Statement: Several patients in the Eribulin Mesylate group in the primary trial survived less than a year.
Primary_evidence: Outcome Measurement:    Overall Survival (OS)   OS was measured from the date of randomization until the date of death from any cause, or the last date the participant was known to be alive. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored. The censoring rules for OS were as follows: 1) if the participant was still alive at data cutoff, the date of data cutoff was considered the end date, and 2) if the participant was lost to follow-up before data cutoff, the date they were last known to be alive was considered the end date. Participants who survived past the end of the study were counted as in the full study period. If death occurred after data cutoff, the end date was to be censored at the time of data cutoff.   Time frame: From date of randomization until date of death from any cause, assessed up to data cutoff date of 12 Mar 2012, or up to approximately 6 years Results 1:    Arm/Group Title: Eribulin Mesylate 1.4 mg/m^2   Arm/Group Description: Eribulin mesylate 1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.   Overall Number of Participants Analyzed: 554   Median (95% Confidence Interval)   Unit of Measure: days  484        (462 to 536) Results 2:    Arm/Group Title: Capecitabine 2.5 g/m^2/Day   Arm/Group Description: Capecitabine : Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days.   Overall Number of Participants Analyzed: 548   Median (95% Confidence Interval)   Unit of Measure: days  440        (400 to 487)